Potential therefore exists in repurposing drugs such as the Lyn inhibitor dasatinib (93) or the Lyn activator tolimidone (248) in a precision medicine approach to SLE treatment where LYN dysregulation is identified. This evidence concerns the gene LYN and systemic lupus erythematosus.